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Summary This study was undertaken to determine humoral immune response to the presence
of anti-immunoglobulin antibodies in children with newly diagnosed type 1 diabetes mellitus,
using as a target cow immunoglobulins, in an attempt to elucidate further complex immuno-
pathogenetic interactions of the disease. Serum immunoglobulin G (IgG) concentrations were
measured by ELISA in 30 children with type 1 diabetes mellitus and 30 healthy matched
normal children. It was found that normal children had a mean IgG level of 7.41 mg/ml while
diabetic individuals had a mean IgG level of 8.52 mg/ml (p<0.00004). On the contrary, the
mean level of IgG in diabetic sera after purification from anti-cow immunoglobulins was
determined to be 7.52 mg/ml. Therefore, there was no significant difference in IgG level in
patients with type 1 diabetes mellitus after removal of anti-cow immunoglobulin antibodies
compared to normal children (p<0.58). Visualization of IgG and immuno-precipitation
confirm that anti-cow immunoglobulins antibodies, which were unrelated to antigen, were co-
precipitated with the antigen-antibody complex. A circulating immunoglobulin reacting with
other immunoglobulins is thus present in children with type 1 diabetes and may well play a
part in the complex immuno-pathogenetic interactions.
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Introduction
Type 1 diabetes mellitus is an autoimmune disease associ-
ated with the presence of different types of autoantibodies.
The presence of these antibodies and the corresponding anti-
gens in the circulation leads to the formation of circulating
immune complexes (CIC). The sequence of this process is
still mostly unknown, and it may take years before β-cell
destruction has proceeded so far that the disease becomes
overt [1–4]. Damage to the target organs in organ-specific
autoimmunity can occur as the result of direct cellular damage
by humoral or cell-mediated mechanisms or by stimulating
autoantibodies or blocking autoantibodies [5]. Young age
and definite signs of islet cell-directed autoimmunity are
known to be factors that affect the speed of the β-cell
destructive process [6].
It has been reported that the incidence of childhood type 1
diabetes mellitus has increased in recent years [7, 8]. Various
exogenous triggers, such as certain dietary factors and viruses,
are thought to induce the immune-mediated process leading
to extensive cell destruction and ultimately to the clinical mani-
festation of type 1 diabetes [9]. The measurement of anti-
bodies has been essential for understanding the epidemiology
of childhood diabetes. In this study, we investigated whether
serum level quantification in children with newly diagnosed
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type 1 diabetes mellitus specific antibodies and immuno-
globulin G (IgG) together furnished novel insight into
infection and immunity.
A number of humoral immune factors are present in the
circulation in the early stages of type 1 diabetic patients
and are thought to play an important part in the complex
immuno-pathological interactions occurring during β-cell
destruction [10–13]. Immunoglobulins, which bind other
immunoglobulins or antibodies, add another facet to the
abnormal immune response of type 1 diabetes mellitus. The
human antibodies, which reacted in this way, were termed
anti-ruminant antibodies [14–16].
The present study was therefore designed to investigate the
presence of these anti-immunoglobulin antibodies in diabetic
children. Anti-immunoglobulin antibodies were defined using
cow immunoglobulins as a target to determine the effect of
anti-immunoglobulin antibodies on the measurement of the
humoral immune response in children with newly diagnosed
type 1 diabetes mellitus in an attempt to clarify some
immuno-pathogenetic aspects of B cell activation during
diabetic disease.
Subjects and Methods
Anti-human IgG antiserum (raised in rabbit), human IgG,
rabbit anti-human IgG conjugated to horseradish peroxidase
(HRP), donkey anti-rabbit IgG conjugated to HRP, diamino-
benzidine, and tetramethylbenzidine were purchased from
Sigma (Sigma-Aldrich Company Ltd, Gillingham, UK) and all
other chemicals were supplied from BDH (VWR International
Ltd, Leicestershire, UK).
Subjects
The study population consisted of 30 normal healthy
children as a control group and 30 children with newly
diagnosed type 1 diabetes mellitus. Sera from normal or
diabetic children where allocated to two groups (A and B).
Each serum sample in group A (from normal children) was
divided into two and assigned to groups 1 and 2 and each
sample in group B (from diabetic children) was assigned
to groups 3 and 4. Groups 1 and 3 were untreated while
groups 2 and 4 were treated with cow immunoglobulins
as outlined in Materials and Methods (Purification of
diabetic sera from the effect of antibodies that interact with
cow immunoglobulins). Normal and diabetic sera were pre-
treated with cow immunoglobulins to investigate whether
this would affect the IgG level as measured by ELISA. Both
group A and B were matched for sex and age with mean age
10.8 years (mean ± SD = 10.8 ± 0.5 years). Medical history,
physical examination and routine laboratory investigations
were completely normal in all subjects of group A. Patients,
had no clinical or laboratory findings indicating other
diseases such as rheumatoid arthritis and viral infection.
Only 30 patients with type 1 diabetes mellitus (group B)
fulfilled these diagnostic criteria and they did not use any
insulin medication prior to this study. Informed parental and
patient consent was obtained in every case and the use of
blood for scientific studies was approved by the local Ethical
Committee. All sera were collected within four months and
stored in small aliquots at −80°C until tested under code.
Electrophoresis of immuno-precipitates on polyacrylamide
gel
Human serum samples were immuno-precipitated with
anti-human IgG developed in rabbit in the presence of cow
immunoglobulins. Human serum samples (25 µl) were diluted
with 1× PBS (475 µl) and, in addition, 75 µl of anti-IgG
antiserum with 1× PBS (425 µl). After dilution, the anti-
serum and serum were mixed to give a final volume of 1 ml
and incubated for 1 h at room temperature. The precipitate
was removed by centrifugation at 13,000 rpm for 5 min in
micro centrifuge and then washed with 100 µl 1× PBS. The
antigen-antibody precipitate was dissolved in 50 µl of 2×
Laemmli sample buffer (0.125 M Tris-HCl pH (6.8), 4% (w/
v) SDS, 20% (w/v) glycerol, 10% (v/v) β-mercaptoethanol,
0.005% (w/v) bromophenol blue) and then incubated at
95°C for 3 min [17]. A fraction of this mixture (25 µl) was
electrophoresed overnight on a 10% polyacrylamide gel at a
constant voltage of 45 V at room temperature. Following
electrophoresis, proteins in gel were visualized by staining
with Coomassie blue staining [18].
Sample preparation for Immunoblotting
Diabetic serum samples (4 µl) were mixed with 20 µl of
2× Laemmli sample buffer, water (20 µl), 1 M iodoacetamide
(8 µl) and then incubated at 95°C for 3 min. A fraction of
this mixture (20 µl) was electrophoresed overnight on a
discontinuous 10% polyacrylamide gel containing 0.1% (w/
v) SDS at a constant voltage of 45 V at room temperature.
Immunoblotting of gel
After electrophoresis, the protein was electroblotted onto
a sheet of nitrocellulose (Millipore HAHY 00010) at
500 mA for 1 h [19, 20]. The nitrocellulose was blocked by
incubation with 5% (w/v) Marvel (dried skimmed milk) in
PBS (phosphate buffered saline; 0.25 M NaCl, 0.0268 M
KCl, 0.081 M Na2HPO4 and 0.0146 M KH2PO4) for 1 h,
washed three times with PBST (PBS containing 0.1% (w/v)
Tween 80; 10 min per wash). The filter was then incubated
with a 1:200 dilution of rabbit anti-human IgG serum in
PBSM (PBS containing 0.1% (w/v) Marvel) for 1 h, followed
by washing three times in PBST. The rabbit immuno-
globulin was detected by incubation in a 1:1000 dilution of
donkey anti-rabbit immunoglobulin conjugated to horseradish
peroxidase in PBSM. The peroxidase was visualized by
staining with 100 ml of a solution containing 0.5 mg/ml ofM. Haroun and M.M. El-Sayed
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diaminobenzidine in 25 mM phosphate buffer pH 7.4,
0.03% (w/v) CoCl2, 0.03% (w/v) ammonium phosphate to
which 5 µl of 100 Vol. H2O2 was added immediately prior to
staining [21].
Human immunoglobulin G measurement by turbidimetric
assay
Human serum samples were titrated previously against
antisera to obtain the optimum optical densities (optimal
precipitation) [22]. Briefly, 8 µl of human serum samples
was diluted with 492 µl of 1× PBS and, in addition, 25 µl of
anti-IgG antiserum (developed in rabbit) with 475 µl of 1×
PBS. After dilution, the antiserum and serum were mixed
and incubated for 1 h at room temperature. At the same
time, the standard human IgG was titrated by adding equal
volumes of antiserum, mixed well and incubated for 1 h
at room temperature. The degree of precipitation was
quantified by measuring the optical density at 600 nm. The
concentration of IgG (mg/ml) was calculated from the
standard dilution series.
Human immunoglobulin G measurement by ELISA
Coating antibody (anti-human IgG antiserum) was diluted
1 in 1000 in 1× coating buffer (0.02 M Tris-HCl, 1.5 M
NaCl, pH 9.0) and 100 µl was added to each of the wells of
a microtiter plate [23, 24]. After overnight incubation at 4°C
the plate was washed 4 times with PBST20 (0.1% (w/v)
(Tween 20 in 1× PBS). Sites unoccupied by antibody were
blocked by addition of 5% (w/v) Marvel in PBS for 1 h at
room temperature followed by washing 6 times with
PBST20. The human serum samples were initially diluted 1
in 2000 in 1× PBS, and 2 fold serial dilutions subsequently
performed on the plate. Diluted samples were allowed to
bind to the first antibody and the plate was then washed 6
times in PBST20.
Rabbit anti-human IgG conjugated to HRP (second anti-
body) was diluted 1 in 1000 in 1× PBS, 100 µl was added
to each well of the microtiter plate, incubated at room
temperature for 1 h and then washed 6 times in PBST20. The
amount of bound second antibody was determined by adding
200 µl of the substrate solution (tetramethylbenzidine 6 mg/
ml in 0.1 M sodium acetate buffer, pH 6.0) to each well.
After incubation in the dark at room temperature for 20 min,
the reaction was stopped by adding 50 µl of 10% (w/v)
H2SO4 to each well after that the absorbance was measured
at 450 nm. The concentration of IgG (mg/ml) was calculated
from the standard dilution series. A standard curve was
constructed by plotting absorbance against concentration for
the standard solutions and the concentration of IgG in the
samples was determined.
Purification of diabetic sera from the effect of antibodies
that interact with cow immunoglobulins
Cow immunoglobulins were isolated previously from cow
serum by affinity chromatography using the appropriate
sepharose-bound antibody (protein A sepharose CL-4B,
Amersham Pharmacia Biotech UK Ltd). The final purified
antibody preparation contains only antigen-specific active
antibody plus a small amount of denatured antibody resulting
from elution procedure. Cow immunoglobulins, 200 µl, at a
concentration of 10 mg/l in PBS, pH 7.2 were mixed with
200 µl of human serum samples from each of 30 diabetic
individuals (diluted 1 in 10) to minimize further cross-
reactivity to human sera. The absorption was carried out for
1h at 37°C, followed overnight at 4°C. The diabetic sera
were clarified by centrifugation at 10000 x g for 15 min at
4°C before testing [25, 26]. The absorption of diabetic sera
with cow immunoglobulins completely removed the positive
reaction of these sera, and then the amount of IgG present
in each of these samples was determined by ELISA as
described above.
Statistical analysis
After tabulating the data, the arithmetic mean for each
group was calculated. The variation or variability in each
group was represented by the standard deviation (SD). The
means of the groups were compared to see if the differences
were significant. Student’s t test was used to assess the
significance of the difference between groups.
Results
The probability that immunoglobulins from diabetic sera
bind and co-precipitates with cow immunoglobulins more
than do immunoglobulins from unaffected individuals was
investigated using immuno-precipitation. Five sera from
diabetic children and five serum samples from an unaffected
participant were immuno-precipitated in the presence of
cow immunoglobulins and the immuno-precipitates were
electrophoresed on a polyacrylamide gel (Fig. 1). Visual
examination of Fig. 1 shows that diabetic sera with cow
immunoglobulins were co-precipitates with the antigen-
antibody complex and co-migrates with the IgG heavy chain.
It is not possible to differentiate between IgG and other
immunoglobulin heavy chains using polyacrylamide gel
electrophoresis therefore, immunoblotting technique with anti-
human IgG was carried out to determine if this increased
interaction included IgG. Visual examination of Fig. 2 shows
that the band intensities in diabetic sera purified from anti-
cow immunoglobulin antibodies was lower than that seen in
diabetic sera without pre-treatment. These results were
validated by measuring the concentration of serum IgG in 5
selected diabetic and normal sera using a turbidimetric assay
(Table 1).Immuno-Pathogenetic Interactions in Diabetic Children
Vol. 40, No. 1, 2007
59
Therefore, the absorption of diabetic sera with cow immuno-
globulins was carried out to eliminate the positive reaction of
these sera and/or investigate whether this would affect the IgG
level as measured by ELISA. Results (Fig. 3) demonstrated
that pretreatment of diabetic sera with cow immuno-
globulins prior to ELISA affected IgG levels where this
dramatically reduced the level of IgG in the sera from
diabetic patients (group 4) while sera from normal children
(group 2) were barely affected by this treatment. The
quantitative analysis of serum IgG level (mean ± SD) found
that group 1 had a mean level of IgG (7.41 ± 0.72 mg/ml)
lower than group 3 (8.52 ± 0.73 mg/ml). These represented
significant increases in IgG level in the sera of group 3
compared to group 1 (p<0.00004). On the contrary, the mean
level of IgG in the sera of group 4 was (7.52 ± 0.85 mg/ml)
within the normal level and there was no significant difference
between group 4 and group 1 (p<0.58). The effect of cow
immunoglobulins treatment on the IgG levels in the sera of
the control group (group 2) was previously investigated and
concluded that the IgG level was within the normal level
after treatment (7.34 ± 0.71 mg/ml; p<0.68). Our results in
this study did not address any statistical significant differences
in sex variation (data not shown).
Discussion
In an attempt to elucidate further complex immuno-
pathogenetic interactions of diabetes mellitus; our finding of
anti-immunoglobulin antibody in diabetic sera, leading to
inaccuracies in immunoglobulin G estimation by ELISA,
represents a move in diagnostic research towards other
possible immunological factors likely to be present in
diabetes. In order to overcome this problem of interfering
due to the effect of anti-immunoglobulin antibodies on ELISA
detection, the diabetic human sera were pre-treated with
cow immunoglobulins to eliminate cross-reaction of other
irrelevant antibodies found in diabetic sera. Interestingly, the
levels of these antibodies decline after purification; hence
this proves that it is not reliable to use the human diabetic
sera directly without previous purification. Thus, this sort of
interaction led to over-estimation of immunoglobulin levels
in diabetic sera, which in turn produces unreliable results.
Type 1 diabetes mellitus is an organ-specific autoimmune
disease in which the insulin-producing beta cells in the
pancreatic islets are selectively eliminated. The autoimmune
attack destroys the beta cells resulting in decreased pro-
duction of insulin and consequently increased levels of
Fig. 1.  Immuno-precipitation and polyacrylamide gel electro-
phoresis of human serum samples with anti-human IgG.
Five diabetic serum samples (lanes 1–5) and five normal
sera (lanes 6–10) were immuno-precipitated with anti-
human IgG developed in rabbit in the presence of cow
immunoglobulins. Lane 11 represents standard human
IgG. H indicates positions of immunoglobulin heavy
chains. The precipitates were washed, dissolved in
Laemmli sample buffer and analyzed by polyacrylamide
gel electrophoresis.
Fig. 2.  Visualization of IgG by immunoblotting after denaturing
polyacrylamide gel electrophoresis. IgG heavy chain
was detected by immunoblotting. Lanes 1 & 2 contained
purified diabetic serum samples and lanes 3, 4, 5, 6 & 7
contained non-purified diabetic serum samples.
Table 1. Effect of anti-cow IgG antibodies on turbidimetric assay.
Normal serum 
sample ID
Group 1 Group 2




Group 3 Group 4
% Decrease in 








6 7.00 6.90 1.43 1 8.20 7.20 12.19
7 7.81 7.80 0.13 2 8.70 7.00 19.54
8 7.50 7.48 0.27 3 9.10 8.50 6.59
9 6.90 6.90 0.00 4 8.70 6.70 22.99
10 7.70 7.66 0.52 5 8.40 7.10 15.48
Serum samples from diabetic and normal children were investigated using polyacrylamide gel electrophoresis (Fig. 1). Groups 1 and 3
were untreated while groups 2 and 4 were treated with cow immunoglobulins.M. Haroun and M.M. El-Sayed
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blood glucose. B-lymphocytes play a major pathogenetic
role by the generation of autoantibodies. Autoantibodies to
beta cells may also contribute to cell destruction by
facilitating either complement-mediated lysis or antibody-
dependent cell-mediated cytotoxicity. However, antibodies
to beta cell proteins are also generated and may be used for
predicting disease in at-risk populations [27]. High levels of
IgM and IgG autoantibodies are associated with many
autoimmune diseases. Evidence suggested that IgG auto-
antibodies are usually pathogenic, whereas secreted IgM,
including IgM autoantibodies produced naturally or as part
of an autoimmune response, may lessen the severity of
autoimmune pathology associated with IgG autoantibodies
[28]. The high prevalence of elevated anti-IgG/antibody
interactions in diabetic patients enhances the clinical utility
of this immune marker due to polyclonal B cell activation or
autoantibodies generation. However, the time course for the
development of antibodies before onset of clinical type 1
diabetes is unknown, which might be most sensitive or
specific for predicting future development of the disease
severity.
The measurement of IgG levels can serve as surrogate
marker to discriminate between antibody positive subjects
at high or low risk for rapid development of diabetes.
Anti-ruminant antibodies effect noticed by a target cow
immunoglobulins showed that the major dramatic effect was
accompanied diabetic children using ELISA measurement.
Therefore, it was necessary to examine with other non-
immunochemical assay, such as immuno-precipitation using
polyacrylamide gel electrophoresis and/or immunoblotting
technique, to find out what sort of complex can be seen due
to this interaction. Results suggested that other antibodies in
diabetic sera interact and co-precipitate with the antigen-
antibody complex heavy chains. The fact that different anti-
bodies recognize different epitopes together with the fact
that the antibody molecules are dimeric means that anti-cow
immunoglobulin antibodies found in diabetic sera is able to
form a cross-linked structure when mixed with antiserum.
Hence, an antibody in antiserum binds to antibodies in
diabetic sera is not indicative that the bound antibody is the
antigen.
Rabbit antisera were reliable for quantitation of serum
IgG in diabetic patients based on ELISA absorbance. Anti-
cow immunoglobulin antibodies found in diabetic sera greatly
overestimate serum IgG concentration measurements in
diabetic children, regardless of the source of antibody used.
The possibility of interference with the antigen-detection
immunoassay for diabetic patients by anti-sera developed in
sheep or goat was previously investigated and concluded that
antigen detection ELISA for captures and detection might
misdiagnose diabetic serum immunoglobulin concentration
(results not shown). Results indicate that this bias will be
avoided if reagents for capture and detection are derived
from different species such as rabbit and this is in agreement
with previous reports [16, 29, 30]. The increased IgG levels
in the sera of diabetics suggest a possible role for IgG in
the pathogenesis of the vascular complications of diabetes
mellitus [27, 31, 32].
In conclusion, the presence of these anti-cow immuno-
globulins in type 1 diabetes mellitus may reflect the increase
production of autoantibodies and then, lead to humoral
immune abnormalities. This is best explained by suggesting
that there is an interaction producing spurious immuno-
precipitation as well as a circulating immunoglobulin which
is capable of binding other autologous immunoglobulins that
may well interact with other immune factors [33]. Moreover,
this study indicates the risk factor of antibodies reacting with
human immunoglobulins in sera from diabetic children.
Furthermore, the autoimmune process begins years before
the beta-cell destruction becomes complete, thereby pro-
viding an opportunity for early intervention that may be used
for predicting disease in at-risk populations. The results of
the present paper point out that the production of specific
antibodies is essentially a question of species specificity. In
addition, address an important question on the protection of
the beta cell from autoimmune attack and the immuno-
genicity of different insulin’s produced in several animal
species.
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